

# ACR-ACNM-SNMMI-SPR PRACTICE PARAMETER FOR PERFORMING FDG-PET/CT IN ONCOLOGY

The American College of Radiology, with more than 40,000 members, is the principal organization of radiologists, radiation oncologists, and clinical medical physicists in the United States. The College is a nonprofit professional society whose primary purposes are to advance the science of radiology, improve radiologic services to the patient, study the socioeconomic aspects of the practice of radiology, and encourage continuing education for radiologists, radiation oncologists, medical physicists, and persons practicing in allied professional fields.

The American College of Radiology will periodically define new practice parameters and technical standards for radiologic practice to help advance the science of radiology and to improve the quality of service to patients throughout the United States. Existing practice parameters and technical standards will be reviewed for revision or renewal, as appropriate, on their fifth anniversary or sooner, if indicated.

Each practice parameter and technical standard, representing a policy statement by the College, has undergone a thorough consensus process in which it has been subjected to extensive review and approval. The practice parameters and technical standards recognize that the safe and effective use of diagnostic and therapeutic radiology requires specific training, skills, and techniques, as described in each document. Reproduction or modification of the published practice parameter and technical standard by those entities not providing these services is not authorized.

## PREAMBLE

This document is an educational tool designed to assist practitioners in providing appropriate radiologic care for patients. Practice Parameters and Technical Standards are not inflexible rules or requirements of practice and are not intended, nor should they be used, to establish a legal standard of care.<sup>1</sup> For these reasons and those set forth below, the American College of Radiology and our collaborating medical specialty societies caution against the use of these documents in litigation in which the clinical decisions of a practitioner are called into question. The ultimate judgment regarding the propriety of any specific procedure or course of action must be made by the practitioner considering all the circumstances presented. Thus, an approach that differs from the guidance in this document, standing alone, does not necessarily imply that the approach was below the standard of care. To the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set forth in this document when, in the reasonable judgment of the practitioner, such course of action is indicated by variables such as the condition of the patient, limitations of available resources, or advances in knowledge or technology after publication of this document. However, a practitioner who employs an approach substantially different from the guidance in this document may consider documenting in the patient record information sufficient to explain the approach taken.

The practice of medicine involves the science, and the art of dealing with the prevention, diagnosis, alleviation, and treatment of disease. The variety and complexity of human conditions make it impossible to always reach the most appropriate diagnosis or to predict with certainty a particular response to treatment. Therefore, it should be recognized that adherence to the guidance in this document will not assure an accurate diagnosis or a successful outcome. All that should be expected is that the practitioner will follow a reasonable course of action based on current knowledge, available resources, and the needs of the patient to deliver effective and safe medical care. The purpose of this document is to assist practitioners in achieving this objective.

---

<sup>1</sup> *Iowa Medical Society and Iowa Society of Anesthesiologists v. Iowa Board of Nursing*, 831 N.W.2d 826 (Iowa 2013) Iowa Supreme Court refuses to find that the "ACR Technical Standard for Management of the Use of Radiation in Fluoroscopic Procedures (Revised 2008)" sets a national standard for who may perform fluoroscopic procedures in light of the standard's stated purpose that ACR standards are educational tools and not intended to establish a legal standard of care. See also, *Stanley v. McCarver*, 63 P.3d 1076 (Ariz. App. 2003) where in a concurring opinion the Court stated that "published standards or guidelines of specialty medical organizations are useful in determining the duty owed or the standard of care applicable in a given situation" even though ACR standards themselves do not establish the standard of care.

## I. INTRODUCTION

This practice parameter was revised collaboratively by the American College of Radiology (ACR), the American College of Nuclear Medicine (ACNM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and the Society for Pediatric Radiology (SPR) to guide physicians interpreting oncologic positron emission tomography/computed tomography (PET/CT) with fluorodeoxyglucose (fluorine-18-2-fluoro-2-deoxy-D-glucose (FDG)) for adult and pediatric patients.

FDG is radiolabeled with 18-F, which is cyclotron-produced, emits positrons, has a half-life of approximately 110 minutes, and is the most commonly used PET oncology imaging radiopharmaceutical. FDG-PET provides

information about glucose metabolism in the body and is a sensitive method for detecting, localizing, staging, and monitoring the effects of therapy for many malignancies. Computed tomography (CT) uses an external source of radiation to produce 3-D images that demonstrate the size, shape, and composition of organs and abnormalities within the body. FDG-PET and CT are proven diagnostic procedures.

Techniques for registration and fusion of images obtained from separate PET and CT scanners have been available for years [1,2]. Combined PET/CT provides both the metabolic information from FDG-PET and the anatomic information from CT in a single examination. The information obtained by PET/CT has been shown to be more accurate in evaluating patients with known or suspected malignancy than either PET or CT alone or PET and CT obtained separately but interpreted together [1,3-17]. The advantages of having both PET and CT in a single device have resulted in rapid dissemination of this technology in the United States. This practice parameter pertains only to integrated PET/CT devices.

Issues related to PET/CT practice include equipment specifications, image acquisition protocols, supervision, interpretation, professional qualifications, and safety. A prior discussion of these issues by representatives of the ACR, the SNMMI, and the Society of Advanced Body Imaging (SABI), (formerly Society of Computed Body Tomography and Magnetic Resonance (SCBT-MR)) is available [18,19].

For the purposes of this practice parameter, the following definitions apply:

**PET/CT scanner:** A hybrid device that includes a single patient table for acquiring a PET scan and CT scan in sequential fashion.

**PET/CT registration:** The reconstructed PET and CT images are spatially co-registered. This is the process of aligning PET and CT image sets that represent the same body volume, such that there is a voxel-by-voxel match for the purpose of attenuation correction as well as combined image display (fusion).

**PET/CT fusion:** PET/CT fusion refers to the simultaneous display of these co-registered PET and CT images.

**PET/CT acquisitions:** The extent of tumor imaging can be tailored to suit the specific indications with the following fields of view considered standard [18]:

1. Whole body (skull vertex to feet)
2. Skull base to mid thighs
3. Vertex to mid thighs
4. Limited region (eg, brain only, chest only)

## **II. INDICATIONS**

Examples of indications for FDG-PET/CT include, but are not limited to, the following:

1. Staging on presentation for guiding initial treatment strategy in patients with a known malignancy
2. Monitoring response to therapy to include determining whether residual abnormalities identified with another imaging modality represent persistent viable tumor or posttreatment changes (inflammation, fibrosis, or necrosis)
3. Restaging in the setting of relapse
4. Attempting to localize the site of primary tumor when metastatic disease is the initial manifestation of malignancy
5. Verifying and localizing "occult" disease, especially in the presence of clinical indicators such as elevated tumor markers
6. Evaluating an abnormality considered "indeterminate" by another imaging modality to determine whether glucose metabolism in that abnormality favors a benign or malignant process
7. Guiding treatment goals, such as curative versus palliative therapy
8. Guiding biopsy and radiation therapy planning.

FDG uptake is variable for different tumor types and can range from high to low uptake. A continuing review of

the literature is recommended to determine the most effective applications.

For information on radiation risks to the fetus, see the [ACR-SPR Practice Parameter for Imaging Pregnant or Potentially Pregnant Patients with Ionizing Radiation](#) [20].

### **III. QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNEL**

#### **A. Physician**

All PET/CT examinations must be performed under the supervision of and interpreted by a physician who has the following qualifications:

Certification in radiology or diagnostic radiology, nuclear radiology, or nuclear medicine by the American Board of Radiology, American Board of Nuclear Medicine, American Osteopathic Board of Radiology, American Osteopathic Board of Nuclear Medicine, the Royal College of Physicians and Surgeons of Canada, or the Collège des Médecins du Québec.

or

At a minimum, completion of a formal Accreditation Council for Graduate Medical Education (ACGME)-approved general nuclear medicine program that must include radiation physics and instrumentation, radiochemistry, radiopharmacology, radiation dosimetry, radiation biology, radiation safety and protection, and quality control (QC). In addition, clinical training in general nuclear medicine is required and must cover technical performance, calculation of dosages, evaluation of images, correlation with other diagnostic modalities, and interpretation.

and

1. Evidence of CME in PET/CT
2. Evidence of ongoing interpretation of oncologic PET/CT

In addition, all physicians supervising and/or interpreting nuclear medicine examinations must satisfy all applicable state and federal regulations as well as any institutional policies that pertain to the in vivo use of radiopharmaceuticals, performance of imaging procedures, and the safe handling of radioactive materials.

### **III. QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNEL**

#### **B. Qualified Medical Physicist**

For qualified medical physicist qualifications, see the [ACR-AAPM Technical Standard for Medical Physics Performance Monitoring of PET/CT Imaging Equipment](#) [21].

### **III. QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNEL**

#### **C. Radiologic and Nuclear Medicine Technologist**

The nuclear medicine technologist performing the PET/CT should be appropriately registered/certified. Additional qualifications for performance of diagnostic CT may also be required, depending upon the technologist's location [22]. The Nuclear Medicine Technology Certification Board (NMTCB) has developed PET and CT specialty examinations ([www.nmtcb.org](http://www.nmtcb.org)) and the American Registry of Radiologic Technologists (ARRT) offers a CT certification examination (<https://www.arrt.org/earn-arrt-credentials/credential-options/computed-tomography>).

For more information regarding training and certification, see the [ACR Practice Parameter for Performing and Interpreting Diagnostic Computed Tomography \(CT\)](#) and the [ACR-ACNM-SNMMI-SPR Practice Parameter for the Use of Radiopharmaceuticals in Diagnostic Procedures](#) [23,24].

### **III. QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNEL**

#### **D. Radiation Safety Officer**

The radiation safety officer (RSO) must meet applicable requirements of the Nuclear Regulatory Commission (NRC) for training as specified in 10 CFR 35.50, or equivalent state regulations [25].

### **IV. FDG-PET/CT EXAMINATION SPECIFICATIONS**

See the [ACR-ASNR-SPR Practice Parameter for the Performance of Computed Tomography \(CT\) of the](#)

[Extracranial Head and Neck](#), the [ACR–SABI–SPR–STR Practice Parameter for the Performance of Thoracic Computed Tomography \(CT\)](#), and the [ACR–SABI–SAR–SPR Practice Parameter for the Performance of Computed Tomography \(CT\) of the Abdomen and Computed Tomography \(CT\) of the Pelvis](#) [26–28].

#### **IV. FDG-PET/CT EXAMINATION SPECIFICATIONS**

##### **A. Written Request for the Examination**

The written or electronic request for an FDG-PET/CT examination should provide sufficient information to demonstrate the medical necessity of the examination and allow for its proper performance and interpretation.

Documentation that satisfies medical necessity includes 1) signs and symptoms and/or 2) relevant history (including known diagnoses). Additional information regarding the specific reason for the examination or a provisional diagnosis would be helpful and may at times be needed to allow for the proper performance and interpretation of the examination.

The request for the examination must be originated by a physician or other appropriately licensed health care provider. The accompanying clinical information should be provided by a physician or other appropriately licensed health care provider familiar with the patient's clinical problem or question and consistent with the state scope of practice requirements. (ACR Resolution 35 adopted in 2006 – revised in 2016, Resolution 12-b)

#### **IV. FDG-PET/CT EXAMINATION SPECIFICATIONS**

##### **B. Patient Preparation [29-31]**

###### **1. Prior to appointment:**

- a. Instruct patients to avoid strenuous activity 24 hours prior to FDG injection.
- b. Recommend low-carbohydrate meals for 24 hours prior to FDG injection.
- c. No caffeine, alcohol, or nicotine 12 hours prior to FDG injection.
- d. Provide fasting instructions (a minimum of 4 hours) with no parenteral nutrition or oral/intravenous fluids containing sugar or dextrose for the same period. No candy, mints, gum, or over-the-counter medicines containing sugar. Even "sugar-free" items may contain traces of sugar.
- e. Encourage oral hydration with a goal of 1 L (34 oz) in 2 hours prior to appointment.
- f. Prescription medications should be taken as directed.
- g. Discontinue metformin 48 hours before the study.
- h. Determine whether there is a history of iodinated contrast allergy and determine renal function if a contrast-enhanced CT portion of the examination has been requested.
- i. If a patient requires sedation or general anesthesia, individual institutional policies should be followed.

#### **IV. FDG-PET/CT EXAMINATION SPECIFICATIONS**

##### **B. Patient Preparation [29-31]**

###### **2. Prior to FDG injection**

Perform pregnancy testing when appropriate and in accordance with institutional policies (see the [ACR–SPR Practice Parameter for Imaging Pregnant or Potentially Pregnant Patients with Ionizing Radiation](#)) [20,31,32].

###### **a. Review the patient's history with attention to:**

- i. Reason for examination (symptoms, diagnoses, and recent imaging examinations)
- ii. Treatment (surgical, radiation, and/or chemotherapy)
- iii. Medications
- iv. Recent trauma/exercise
- v. Presence of concurrent infection
- vi. Presence of diabetes
- vii. Specific details and dates should be obtained whenever possible.

###### **b. Consider premedications:**

- i. Anxiolytics can be administered in patients with claustrophobia or anxiety. Oral alprazolam (0.5 mg given 10–60 minutes prior to FDG injection) is an option. Patients must be counseled against driving

given the medication's sedative and motor-impairing effects, and it is recommended that the patient should sign a form agreeing to this.

c. Oral beta-blockers (such as propranolol 20 mg) can be administered 60 minutes prior to injection or benzodiazepines (such as diazepam 5 mg) 10–30 minutes prior to injection to help minimize physiologic brown fat uptake. For pediatric patients, 0.10 mg/kg of oral diazepam or 1 mg/kg oral propranolol can be given, but the combination of warming blankets and propranolol in this patient population best reduces brown fat uptake [33]. Keep the patient warm:

The patient should be advised to remain warm 24 hours prior to FDG injection. In addition, the patient can be kept warm with warming blankets prior to and after FDG injection. This helps minimize physiologic brown fat and may be preferable to giving the patient medications for this purpose.

d. Serum glucose analysis performed immediately prior to FDG administration (<200 mg/dL acceptable)

i. If the serum glucose is >200 mg/dL, but <300 mg/dL, contact the interpreting physician for further instructions. If the serum glucose is >300 mg/dL, then the patient should be rescheduled. Of note, if the patient did in fact properly follow fasting instructions, the referring physician may need to be informed about testing the patient for diabetes and/or consider referring the patient to urgent care or the emergency department in cases of extremely high blood glucose levels.

e. Diabetic patient guidelines:

i. PET scan should be scheduled early in the morning (if possible) as this is the time that most diabetic patients have the lowest glucose level. However, some diabetic patients may have lower glucose levels in the afternoon, and for these patients an afternoon appointment is preferable.

ii. Diabetic patients should take their usual insulin the day before. After midnight, patients should fast (except for water).

iii. A low- or no-carbohydrate diet the evening prior to the PET/CT may improve glycemic control.

iv. On the morning of the PET scan, hold all insulin if FDG injection is scheduled in the early morning.

v. Oral diabetic medications can be taken as prescribed (see prior comments on metformin).

vi. If PET scan is scheduled after 10 AM, patient should eat a low-carbohydrate breakfast at least 4 hours before the injection and should receive half of the usual regular (short-acting) insulin. Do not use long-acting or mixed (70/30) insulin after midnight.

vii. If the patient is on an insulin pump, it is preferred that it is turned off 4 hours prior to the study, but if unable to, the setting should be on the night/basal setting during the PET scan. After the PET scan, settings can be adjusted as prescribed.

viii. After completion of the PET scan, patients should be encouraged to eat a meal immediately. It may be advisable for patients to take half of the usual morning dosage of insulin with the post-PET meal.

Technologist should inform the interpreting physician if the patient has hyperglycemia >200 mg/dL or hypoglycemia with symptoms. In these situations, waiting approximately 20 to 30 minutes and repeating a finger-stick glucose measurement should be considered prior to rescheduling the patient.

#### **IV. FDG-PET/CT EXAMINATION SPECIFICATIONS**

##### **B. Patient Preparation [29-31]**

###### **3. Following injection (uptake period)**

a. Have the patient remain seated or recumbent in a quiet room during uptake period (decreases muscle uptake). Additionally, in adult patients with head and neck cancer, oral alprazolam 0.5 mg given immediately after FDG injection reportedly can reduce skeletal muscle uptake that can impede lesion detection and confound scan interpretation [35].

b. The uptake room should be dimly lit if the patient is to undergo brain imaging.

c. Patients should void immediately prior to being positioned on the PET/CT table for imaging. In special circumstances, intravenous hydration, diuretic administration, and/or bladder catheterization can be used to reduce radiation burden and artifacts related to accumulated physiologic radiopharmaceutical activity in the ureters and urinary bladder.

d. Consider use of sedation as necessary in younger children or developmentally delayed patients (see the

## **IV. FDG-PET/CT EXAMINATION SPECIFICATIONS**

### **B. Patient Preparation [29-31]**

#### **4. Lactating Patients**

- a. Nursing mothers should express/pump milk prior to the study.
- b. Per recent Advisory Committee for Medical use of Isotopes (ACMUI) guidelines, nursing should be interrupted for 4 hours following 18-F FDG injection [36].

## **IV. FDG-PET/CT EXAMINATION SPECIFICATIONS**

### **C. Radiopharmaceutical**

For adults, the generally accepted range for administered activity of FDG is 185 to 740 MBq (5-20 mCi) [37]. However, the administered activity could be below 5 mCi with a weight-based approached or depending upon the type of PET detector being used.

For children, the administered activity of FDG should be determined based on body weight and should be as low as reasonably achievable (ALARA) for diagnostic image quality<sup>1</sup>. Per the 2016 Update of the North American Consensus Guidelines, pediatric FDG administered activity should be 3.7–5.2 MBq/kg (0.10-0.14 mCi/kg), a minimum of 26 MBq (0.7 mCi) for body and 3.7 MBq/kg (0.10 mCi/kg), a minimum of 14 MBq (0.37 mCi) for head [38].

The specific administered activity typically depends upon the local imaging protocol. The local protocol may require a standard activity, or the activity may vary as a function of various parameters, such as patient size, scanning mode (2-D versus 3-D), percentage of scan bed (slice) overlap, or clinical indication. For variable dosages, other means of determining the administered activity can be based upon a combination of factors, for example, as outlined in European Association of Nuclear Medicine guidelines [29], which use the patient's weight, duration of bed positions in minutes, and percent bed position overlap in certain PET/CT systems (some systems do not use bed positions). The variable dose calculation's goal is to optimize a personalized dosage with the ALARA principle. Without a dedicated dosage injector with the ability to precisely elute a calculated dosage, a fixed dose with a range may be more practical for adults.

With PET/CT, the radiation dose to the patient is the combination of the dose from the PET radiopharmaceutical and the dose from the CT portion of the examination. Lower administered activities or changes in CT parameters resulting in decreased radiation dose may be appropriate with advances in PET/CT technology.

When feasible, the radiopharmaceutical should be injected intravenously at a site away from sites of known or suspected disease. If peripheral IV access is not achievable, a central line can be used but must be sufficiently flushed with normal saline.

<sup>1</sup>For more specific guidance on pediatric dosing, please refer to the *Pediatric Radiopharmaceutical Administered Doses: 2010 North American Consensus Guidelines*.

## **IV. FDG-PET/CT EXAMINATION SPECIFICATIONS**

### **D. Protocol for CT Imaging**

The CT performed as part of a PET/CT examination provides attenuation-correction information and diagnostic information that may be relevant to both PET interpretation and overall patient care. A variety of protocols exist for performing the CT scan in the context of PET/CT scanning. In some cases, low-dose CT scans are designed primarily to provide attenuation correction and anatomic localization. In other cases, the CT portion of the examination is performed with intravenous and/or oral contrast media and optimized CT parameters designed to lower image noise. If a diagnostic CT scan is requested as part of PET/CT, the CT protocol appropriate for the body region(s) requested should be used. Regardless of the CT technique used, a careful review of CT images is

necessary for comprehensive interpretation of the PET/CT examination.

For a diagnostic CT scan of the abdomen and/or pelvis, intraluminal gastrointestinal contrast media may be administered to improve visualization of the gastrointestinal tract unless medically contraindicated or unnecessary for the clinical indication. This may be positive-contrast media such as a dilute (2%) solution of a water-soluble iodinated contrast agent—diluted barium sulfate or diatrizoic acid or negative-contrast media such as water [39]. Highly concentrated barium collections may result in an attenuation-correction artifact that may lead to overestimation of the regional FDG concentration and should be avoided. Dilute barium sulfate and oral iodinated contrast media cause less overestimation and are less likely to have an adverse impact on PET image quality [40-42].

When indicated, the CT scan can be performed with intravenous contrast media using appropriate injection techniques. It has been shown that there is no statistically significant or clinically significant interference with standardized uptake values (SUVs) on PET/CT due to intravenous contrast administration [43].

Breathing patterns during CT acquisition should be optimized so that the positions of the diaphragm on the PET emission and the CT transmission images match as closely as possible.

If a single breath-hold technique is used for CT imaging, optimal alignment of the PET and CT images is obtained with respiration suspended in the quiet end-expiratory (end-tidal volume) phase. If respiration is not suspended during CT imaging, the patient should be coached on shallow/quiet breathing. To optimize breathing pattern, gating of the PET and/or CT can be performed in more modern PET/CT scanners.

#### **IV. FDG-PET/CT EXAMINATION SPECIFICATIONS**

##### **E. Protocol for PET Imaging**

Emission images are acquired immediately after CT and are generally obtained 60 minutes following radiopharmaceutical administration. However, this time period may be shorter (no less than 45 minutes) or longer for certain trials or unique clinical situations. Note that consistency of SUV measurements depends on strict observance of the uptake time [44].

Emission image acquisition time typically varies from 1–5 minutes or longer per bed position for body imaging and is based on the administered activity, patient body weight, and the sensitivity of the PET device (as determined largely by the detector composition and acquisition method). Acquisition time can be adjusted in certain clinical situations to provide higher count images in a given anatomic area.

Iterative reconstruction techniques have largely replaced filtered back projection, and when used with time of flight, image quality can be maintained while reducing administered FDG activity. Of note, new scanners may utilize artificial intelligence/machine learning–based reconstructions or Bayesian penalized-likelihood reconstruction algorithms as methods.

Semiquantitative estimation of FDG accumulation using the SUV is based on local radioactivity concentration measured on images corrected for attenuation and normalized for the injected activity and body weight, lean body mass, or body surface area. The accuracy of SUV measurements depends on the accuracy of the calibration of the PET device, among other factors. SUV is utilized in determining tumor response over time. Measures should be taken to minimize the factors that may affect it and should include using the same scanner configuration on subsequent examinations (including reconstruction algorithms, attenuation maps, etc), maintaining the same interval between injection and scanning, avoiding infiltration of injected activity, and using the same measurement techniques (volume-of-interest volumes, max/peak/mean measurements). Some factors that affect SUV currently remain beyond control, such as variations in serum glucose and patient motion/breathing-related attenuation-correction artifacts [45].

Recording changes in the intensity of FDG uptake with semiquantitative measurements, expressed in absolute values and percent changes, may be appropriate in some clinical scenarios. However, the technical protocol and analysis of images need to be consistent in the 2 data sets.

## **IV. FDG-PET/CT EXAMINATION SPECIFICATIONS**

### **F. Interpretation**

With integrated PET/CT systems, the software packages typically provide a comprehensive platform for image review, including registered and aligned CT images, FDG-PET images with and without attenuation correction, and PET/CT fusion images in the axial, coronal, and sagittal planes. In addition, maximum-intensity projection (MIP) images of the PET examination should be generated for review. FDG-PET images with and without attenuation correction should be available for review.

On whole-body scans, studies have shown that FDG-PET imaging of the brain is relatively insensitive for detecting cerebral and cerebellar metastases. This is due in part to the high physiologic FDG uptake in the normal gray matter, and thus images of the brain should be reviewed with attention to both FDG-avid and photopenia (non-FDG-avid) areas.

Although the pattern of FDG uptake and associated CT findings as well as correlation with history, physical examination, and other imaging modalities are usually the most helpful in differentiating benign from malignant lesions, semiquantitative estimates (eg, SUVs) may also be of value, especially for evaluating changes with time or therapy.

Tissues other than neoplastic disease may show substantial FDG uptake. Other conditions may lead to poor FDG uptake in neoplastic tissue. The following list, although not all-inclusive, includes the most commonly encountered situations in which FDG uptake is caused by processes other than malignant disease and in which FDG uptake does not occur despite the presence of malignant disease:

## **IV. FDG-PET/CT EXAMINATION SPECIFICATIONS**

### **F. Interpretation**

#### **1. Situations that can lead to benign FDG-PET/CT uptake**

##### **a. Physiologic uptake**

- Salivary glands and lymphoid tissue in the head and neck
- Thyroid
- Orbital, speech, and tongue muscle (especially in children)
- Brown adipose tissue
- Thymus, especially in children and young adults
- Lactating breast
- Areola
- Skeletal and smooth muscle (more marked with recent exercise or hyperinsulinemia). Laryngeal muscle uptake with phonation. Masticator muscle uptake with chewing. Diaphragm/intercostal muscle uptake with crying (pediatric) or labored breathing.
- Gastrointestinal tract (eg, esophagus, stomach, bowel, and anal sphincter, with large-bowel uptake, which is often very intense in patients using metformin, uptake in the cecal region)
- Urinary tract structures (containing excreted FDG)
- Female genital tract (eg, uterus during menses, corpus luteum cyst)
- Skeletal: physes in children, ischiopubic synchondrosis
- Axillary node uptake (from infiltration at site of injection or recent tattoo in same extremity or secondary to recent vaccination for COVID 19)

## **IV. FDG-PET/CT EXAMINATION SPECIFICATIONS**

### **F. Interpretation**

#### **1. Situations that can lead to benign FDG-PET/CT uptake**

##### **b. Infectious and inflammatory processes**

- Postprocedural inflammation/infection/hematoma, biopsy site, thoracentesis, paracentesis, amputation site
- Postradiation inflammation (eg, radiation pneumonitis)
- Postchemotherapy changes, including inflammation and necrosis
- Local inflammatory disease, especially granulomatous processes (eg, sarcoidosis, fungal, and mycobacterial disease)
- Ostomy site (eg, trachea, colon), feeding and drainage tubes
- Injection site
- Thyroiditis
- Esophagitis, gastritis, inflammatory bowel disease, appendicitis
- Acute and occasionally chronic pancreatitis
- Acute cholangitis and cholecystitis
- Osteomyelitis, recent fractures, joint prostheses
- Lymphadenitis and reactive lymph nodes (especially in children)
- Vascular inflammation, including vasculitis and atherosclerotic disease

#### **IV. FDG-PET/CT EXAMINATION SPECIFICATIONS**

##### **F. Interpretation**

###### **1. Situations that can lead to benign FDG-PET/CT uptake**

###### **c. Benign tumor or tumor-like conditions**

- Pituitary adenoma
- Adrenal adenoma
- Thyroid gland follicular adenoma
- Salivary gland tumors (eg, Warthin, pleomorphic adenoma)
- Colonic adenomatous polyps
- Ovarian thecoma and cystadenoma
- Skeletal: aneurysmal bone cyst, fibrous cortical defect, enchondroma, giant-cell tumor, benign fibro-osseous lesions (in pediatric patients)
- Plexiform neurofibroma
- Leiomyoma

#### **IV. FDG-PET/CT EXAMINATION SPECIFICATIONS**

##### **F. Interpretation**

###### **1. Situations that can lead to benign FDG-PET/CT uptake**

###### **d. Hyperplastic and dysplastic conditions**

- Graves disease
- Cushing disease
- Bone marrow hyperplasia (eg, anemia, colony-stimulating factor)
- Thymic rebound hyperplasia (after chemotherapy)
- Fibrous dysplasia
- Paget disease

#### **IV. FDG-PET/CT EXAMINATION SPECIFICATIONS**

##### **F. Interpretation**

###### **1. Situations that can lead to benign FDG-PET/CT uptake**

###### **e. Artifacts**

- Misalignment between PET and CT data can cause attenuation-correction artifacts. Fusion images and PET images without attenuation correction can be used to help identify these artifacts.
- Inaccuracies in converting from polychromatic CT energies to the 511-keV energy of annihilation radiation can cause artifacts around implanted devices, metal, highly concentrated iodinated contrast, or dense barium, although these artifacts are less common with newer conversion algorithms.
- Motion artifact
- Edge artifact
- Metallic artifact
- Truncation artifact

#### **IV. FDG-PET/CT EXAMINATION SPECIFICATIONS**

##### **F. Interpretation**

###### **2. Situations that can lead to false-negative FDG-PET/CT interpretation:**

- Small lesion size (<2 × resolution of the system)
- Hyperglycemia and hyperinsulinemia
- Recent therapy
- Chemotherapy
- Radiation therapy
- Steroid therapy
- Tumors with low metabolic activity
- Certain low-grade or well-differentiated tumors, such as mucinous neoplasms to include lung adenocarcinoma in situ
- Prostate carcinoma
- Carcinoid tumor and islet cell tumors
- Medullary thyroid cancer
- Lobular carcinoma of the breast
- Hepatocellular tumors, including well-differentiated hepatocellular carcinoma
- Indolent lymphoma, including marginal zone lymphoma and small-cell lymphocytic lymphoma

#### **V. EQUIPMENT SPECIFICATIONS**

See the [ACR–AAPM Technical Standard for Medical Physics Performance Monitoring of PET/CT Imaging Equipment](#), the [ACR–ASNR–SPR Practice Parameter for the Performance of Computed Tomography \(CT\) of the Extracranial Head and Neck](#), the [ACR–SABI–SPR–STR Practice Parameter for the Performance of Thoracic Computed Tomography \(CT\)](#), and the [ACR–SPR Practice Parameter for the Performance of Computed Tomography \(CT\) of the Abdomen and Computed Tomography \(CT\) of the Pelvis](#) [21,26–28].

Appropriate emergency equipment and medications must be immediately available to treat adverse reactions associated with administered medications, to include iodinated contrast media. The equipment and medications should be monitored for inventory and drug expiration dates on a regular basis. The equipment, medications, and other emergency support must also be appropriate for the range of ages and sizes in the patient population.

A fusion workstation with the capability to display PET, CT, and fused images with different percentages of PET and CT blending should also be available. The workstation should also have the capability to measure SUV with volumetric ROI.

PET/CT scanning done specifically for radiation therapy planning should be performed with a flat table top, immobilization devices as needed, and the use of appropriate positioning systems in order to best match patient positioning during radiation therapy.

#### **VI. DOCUMENTATION**

Reporting should be in accordance with the [ACR Practice Parameter for Communication of Diagnostic Imaging](#)

## Findings [46].

The technique section of the report should include the radiopharmaceutical (eg, FDG), the administered activity, route and site of administration, as well as any pharmaceuticals administered (eg, diuretics, benzodiazepines). The serum glucose level at the time of radiopharmaceutical administration should be reported as well as patient weight, time from injection to scanning, and technique for calculating SUVs (ie, body weight, lean body weight, or body surface area) [47].

Details of oral or intravenous contrast agents, if used for the CT attenuation-correction portion of the examination, should also be reported, to include the volume and route of administration. Other information relevant to contrast administration, such as steroid preparation, prehydration, or dialysis history, should be included. The report should also include documentation of contrast reactions and subsequent treatment, if observed during the examination.

The findings section should include description of the location, extent, and intensity of abnormal FDG uptake in relation to normal comparable tissues and should describe the relevant morphologic findings on the CT images. Ideally, image and series numbers should also be included. Additionally, background activity (eg, mediastinal blood pool and/or volumetric normal liver) should be measured and reported to help ensure comparable SUVs [48]. Often, injection-site infiltrates, such as in arms, or attenuation-correction errors can significantly alter SUVs in lesions, leading to false conclusions. An estimate of the intensity of FDG uptake can be provided with the SUV, and/or the intensity of uptake may be described as mild, moderate, or intense in relation to the background uptake in normal hepatic parenchyma or the mediastinal blood pool.

If the CT scan was requested and performed as a diagnostic examination, the CT component of the examination should be reported separately to satisfy regulatory, administrative, or reimbursement requirements. In that case, the PET/CT report should refer to the diagnostic CT scan report for findings not related to the PET/CT combined findings [49-51]. Even if the CT scan was not requested as a diagnostic examination, clinically important findings (eg, pneumothorax, aortic aneurysm, bowel obstruction, pneumoperitoneum, fracture, non-FDG-avid malignancy) on the CT scan should be reported.

When PET/CT is performed for monitoring therapy, a comparison of extent and intensity of uptake may be summarized as metabolic progressive disease, metabolic stable disease, metabolic partial response, or metabolic complete response using published criteria for these categories [52,53].

## **VII. EQUIPMENT QC**

PET performance monitoring should be in accordance with the [ACR–AAPM Technical Standard for Nuclear Medical Physics Performance Monitoring of Gamma Cameras](#) and the [ACR–AAPM Technical Standard for Medical Physics Performance Monitoring of PET/CT Imaging Equipment](#) [21,54].

CT monitoring should be in accordance with the [ACR–AAPM Technical Standard for Diagnostic Medical Physics Performance Monitoring of Computed Tomography \(CT\) Equipment](#) [55].

The QC procedures for PET/CT should include both the PET procedures and the CT procedures according to the ACR Technical Standards. The QC procedures for PET should include a calibration measurement of activity in a phantom containing a known radiopharmaceutical concentration, generally as a function of axial position within the scanner field of view. The QC procedures for the CT should include air and water calibrations in Hounsfield units for a range of kV. A daily check on the stability of the individual detectors should also be performed to identify detector failures and drifts.

In addition, for PET/CT, the alignment between the PET and CT scanners should be checked periodically. Such a check should determine an offset between the PET and CT scanners that is incorporated into the fused image display to ensure accurate image alignment.

## **VIII. RADIATION SAFETY IN IMAGING**

Radiologists, medical physicists, non-physician radiology providers, radiologic technologists, and all supervising physicians have a responsibility for safety in the workplace by keeping radiation exposure to staff, and to society as a whole, "as low as

reasonably achievable" (ALARA) and to assure that radiation doses to individual patients are appropriate, taking into account the possible risk from radiation exposure and the diagnostic image quality necessary to achieve the clinical objective. All personnel who work with ionizing radiation must understand the key principles of occupational and public radiation protection (justification, optimization of protection, application of dose constraints and limits) and the principles of proper management of radiation dose to patients (justification, optimization including the use of dose reference levels). [https://www-pub.iaea.org/MTCD/Publications/PDF/PUB1775\\_web.pdf](https://www-pub.iaea.org/MTCD/Publications/PDF/PUB1775_web.pdf)

Nationally developed guidelines, such as the [ACR's Appropriateness Criteria](#)<sup>®</sup>, should be used to help choose the most appropriate imaging procedures to prevent unnecessary radiation exposure.

Facilities should have and adhere to policies and procedures that require ionizing radiation examination protocols (radiography, fluoroscopy, interventional radiology, CT) to vary according to diagnostic requirements and patient body habitus to optimize the relationship between appropriate radiation dose and adequate image quality. Automated dose reduction technologies available on imaging equipment should be used, except when inappropriate for a specific exam. If such technology is not available, appropriate manual techniques should be used.

Additional information regarding patient radiation safety in imaging is available from the following websites – Image Gently<sup>®</sup> for children ([www.imagegently.org](http://www.imagegently.org)) and Image Wisely<sup>®</sup> for adults ([www.imagewisely.org](http://www.imagewisely.org)). These advocacy and awareness campaigns provide free educational materials for all stakeholders involved in imaging (patients, technologists, referring providers, medical physicists, and radiologists).

Radiation exposures or other dose indices should be periodically measured by a Qualified Medical Physicist in accordance with the applicable ACR Technical Standards. Monitoring or regular review of dose indices from patient imaging should be performed by comparing the facility's dose information with national benchmarks, such as the ACR Dose Index Registry and relevant publications relying on its data, applicable ACR Practice Parameters, NCRP Report No. 172, Reference Levels and Achievable Doses in Medical and Dental Imaging: Recommendations for the United States or the Conference of Radiation Control Program Director's National Evaluation of X-ray Trends; 2006, 2009, amended 2013, revised 2023 (Res. 2d).

## **IX. QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION**

Policies and procedures related to quality, patient education, infection control, and safety should be developed and implemented in accordance with the ACR Policy on Quality Control and Improvement, Safety, Infection Control, and Patient Education appearing under the heading *ACR Position Statement on Quality Control & Improvement, Safety, Infection Control, and Patient Education* on the ACR website (<https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Quality-Control-and-Improvement>).

In all pediatric patients, the lowest exposure factors should be chosen that would produce images of diagnostic quality.

For specific issues regarding CT quality control, see the [ACR Practice Parameter for Performing and Interpreting Diagnostic Computed Tomography \(CT\)](#) [23].

For specific issues regarding PET and PET/CT quality control, see Section VIII on Equipment Quality Control.

Equipment performance monitoring should be in accordance with the [ACR–AAPM Technical Standard for Diagnostic Medical Physics Performance Monitoring of Computed Tomography \(CT\) Equipment](#) [55].

## **ACKNOWLEDGEMENTS**

This practice parameter was revised according to the process described under the heading *The Process for Developing ACR Practice Parameters and Technical Standards* on the ACR website (<https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards>) by the Committee on Practice Parameters and Technical Standards - Nuclear Medicine and Molecular Imaging of the ACR Commission on Nuclear Medicine and Molecular Imaging and the Committee on Practice Parameters – Pediatric Imaging of the ACR Commission on Pediatric Radiology, in collaboration with the ACNM, the SNMMI, and the SPR.

Writing Committee – members represent their societies in the initial and final revision of this practice parameter

### **ACR**

Twyla B. Bartel, DO, MBA, FACNM, Chair

Richard K. J. Brown, MD, FACP

### **ACNM**

Yang Lu, MD, PhD, FACNM

Guofan Xu, MD, PhD

Helen R. Nadel, MD

Katherine Zukotynski, MD, PhD, FRCPC

SNMMI

Patrick M Colletti, MD, FACNM, FSNMMI

Hossein Jadvar, MD, PhD, MPH, MBA, FACNM, FSNMMI

Andrei Iagaru, MD

Gary Ulaner, MD, PhD, FACNM

SPR

Hollie A. Lai, MD

Marguerite T. Parisi, MD, MS

Stephan D. Voss, MD

Committee on Practice Parameters and Technical Standards – Nuclear Medicine and Molecular Imaging

(ACR Committee responsible for sponsoring the draft through the process)

Munir V. Ghesani, MD, FACP, Co-Chair

Andrew Kaiser, MD

Rathan M. Subramaniam, MD, PhD, MPH, Co-Chair

Jeffrey S. Kempf, MD, FACP

Esma A. Akin, MD, FACP

Justin G. Peacock, MD

Alexandru C. Bageac, MD, MBA

Syam P. Reddy, MD

Twyla B. Bartel, DO, MBA

Eric M. Rohren, MD, PhD

Elizabeth H. Dibble, MD

Levi Sokol, MD

K. Elizabeth Hawk, MD, MS, PhD

Andrew T. Trout, MD

Eric Hu, MD

Committee on Practice Parameters – Pediatric Radiology

(ACR Committee responsible for sponsoring the draft through the process)

Terry L. Levin, MD, FACP, Chair

Jane Sun Kim, MD

John B. Amodio, MD, FACP

Jennifer A Knight, MD

Jesse Berman, MD

Jessica Kurian, MD

Tara M. Catanzano, MB, BCh

Matthew P. Lungren, MD, MPH

Harris L. Cohen, MD, FACP

Helen R. Nadel, MD

Kassa Darge, MD, PhD

Erica Poletto, MD

Dorothy L. Gilbertson-Dahdal, MD

Richard B. Towbin, MD, FACP

Lauren P. Golding, MD

Andrew T. Trout, MD

Safwan S. Halabi, MD

Esben S. Vogelius, MD

Jason Higgins, DO

Don C. Yoo, MD, FACP, Chair of the Commission Nuclear Medicine and Nuclear Medicine

Richard A. Barth, MD, FACP, Chair, Commission on Pediatric Radiology

David B. Larson, MD, MBA, Chair, Commission on Quality and Safety

Mary S. Newell, MD, FACP, Chair, Committee on Practice Parameters and Technical Standards

## Comment Reconciliation Committee

Derrick Siebert, MD, Chair	Hollie A. Lai, MD
K. Elizabeth Hawk, MD, MS, PhD Co-Chair	David B. Larson, MD, MBA
Isamettin A. Aral, MD, MS	Paul A. Larson, MD, FACR
Twyla B. Bartel, DO, MBA	Terry L. Levin, MD, FACR
Richard A. Barth, MD, FACR	Yang Lu, MD, PhD, FACNM
David Brandon, MD	Helen R. Nadel, MD
Richard K.J. Brown, MD, FACR	Mary S. Newell, MD, FACR
Patrick M Colletti, MD, FACNM, FSNMMI	Marguerite T. Parisi, MD, MS
Richard Duszak Jr., MD, FACR	Vincent Seghers, MD, PhD
Saeed Elojeimy, MD, PhD	Rathan M. Subramaniam, MD, PhD, MPH
Munir V. Ghesani, MD, FACR	Gary Ulaner, MD, PhD, FACNM
Andrei Iagaru, MD	Stephan D. Voss, MD
Arnold Jacobson, MD	Guofan Xu, MD, PhD
Hossein Jadvar, MD, PhD, MPH, MBA, FACNM, FSNMMI	Don C. Yoo, MD, FACR
Amy Kotsenas, MD, FACR	Katherine Zukotynski, MD, PhD, FRCPC

## **REFERENCES**

1. Putzer DD, Henninger BB, Kovacs PP, et al. Accuracy and feasibility of three different methods for software-based image fusion in whole-body PET and CT. *Q J Nucl Med Mol Imaging* 60:172-81, .
2. Townsend DD, Beyer TT. A combined PET/CT scanner: the path to true image fusion. *Br J Radiol* 75 Spec No:S24-30, .
3. Akin EE, Kuhl EE, Zeman RR. The role of FDG-PET/CT in gynecologic imaging: an updated guide to interpretation and challenges. *Abdom Radiol (NY)* 43:2474-2486, .
4. Akin EA, Qazi ZN, Osman M, Zeman RK. Clinical impact of FDG PET/CT in alimentary tract malignancies: an updated review. [Review]. *Abdominal Radiology*. 45(4):1018-1035, 2020 04.
5. Bar-Shalom RR, Yefremov NN, Guralnik LL, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. *J Nucl Med* 44:1200-9, .
6. Bartel TB, Haessler J, Brown TL, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. *Blood*. 114(10):2068-76, 2009 Sep 03.
7. Berriolo-Riedinger A, Becker S, Casasnovas O, Vander Borgh T, Edeline V. Role of FDG PET-CT in the treatment management of Hodgkin lymphoma. [Review]. *Cancer Radiotherapie*. 22(5):393-400, 2018 Sep. *Cancer Radiother*. 22(5):393-400, 2018 Sep.
8. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. *Journal of Clinical Oncology*. 32(27):3059-68, 2014 Sep 20. *J Clin Oncol*. 32(27):3059-68, 2014 Sep 20.
9. Fukui MM, Blodgett TT, Meltzer CC. PET/CT imaging in recurrent head and neck cancer. *Semin Ultrasound CT MR* 24:157-63, .
10. Kandathil A, Kay FU, Butt YM, Wachsmann JW, Subramaniam RM. Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non-Small Cell Lung Cancer. [Review]. *Radiographics*. 38(7):2134-2149, 2018 Nov-Dec.
11. Katal S, Gholamrezanezhad A, Kessler M, Olyaei M, Jadvar H. PET in the Diagnostic Management of Soft Tissue Sarcomas of Musculoskeletal Origin. [Review]. *PET clinics*. 13(4):609-621, 2018 Oct.
12. Kim JW, Roh JL, Kim JS, et al. (18)F-FDG PET/CT surveillance at 3-6 and 12 months for detection of recurrence and second primary cancer in patients with head and neck squamous cell carcinoma. *Br J Cancer*. 109(12):2973-9, 2013 Dec 10.
13. Kunawudhi AA, Wong AA, Alkasab TT, Mahmood UU. Accuracy of FDG-PET/CT for Detection of Incidental Pre-Malignant and Malignant Colonic Lesions - Correlation with Colonoscopic and Histopathologic Findings. *Asian Pac J Cancer Prev* 17:4143-7, .
14. Petersen RR, Hess SS, Alavi AA, Høilund-Carlsen PP. Clinical impact of FDG-PET/CT on colorectal cancer staging and treatment strategy. *Am J Nucl Med Mol Imaging* 4:471-82, .
15. Schöder HH, Erdi YY, Larson SS, Yeung HH. PET/CT: a new imaging technology in nuclear medicine. *Eur J Nucl*

Med Mol Imaging 30:1419-37, .

**16.** Singnurkar A, Wang J, Joshua AM, Langer DL, Metser U. 18F-FDG-PET/CT in the Staging and Management of Melanoma: A Prospective Multicenter Ontario PET Registry Study. Clinical Nuclear Medicine. 41(3):189-93, 2016 Mar.

**17.** Skalski JJ, Wahl RR, Meyer CC. Comparison of mutual information-based warping accuracy for fusing body CT and PET by 2 methods: CT mapped onto PET emission scan versus CT mapped onto PET transmission scan. J Nucl Med 43:1184-7, .

**18.** American Medical Association. AMA CPT® Codebook. Chicago, IL; 2020.

**19.** Coleman RR, Delbeke DD, Guiberteau MM, et al. Concurrent PET/CT with an integrated imaging system: intersociety dialogue from the joint working group of the American College of Radiology, the Society of Nuclear Medicine, and the Society of Computed Body Tomography and Magnetic Resonance. J Nucl Med 46:1225-39, .

**20.** American College of Radiology. ACR-SPR Practice Parameter for Imaging Pregnant or Potentially Pregnant Patients with Ionizing Radiation. Available at: <https://gravitas.acr.org/PPTS/GetDocumentView?docId=23+&releaseId=2>

**21.** American College of Radiology. ACR-AAPM Technical Standard for Medical Physics Performance Monitoring of PET/CT Imaging Equipment. Available at <https://gravitas.acr.org/PPTS/GetDocumentView?docId=198+&releaseId=2>

**22.** Fusion imaging: a new type of technologist for a new type of technology. July 31, 2002. J Nucl Med Technol. 2002 Dec;30(4):201-4.

**23.** American College of Radiology. ACR-SPR Practice Parameter for Performing and Interpreting Diagnostic Computed Tomography (CT). Available at <https://gravitas.acr.org/PPTS/GetDocumentView?docId=132+&releaseId=2>

**24.** American College of Radiology. ACR-ACNM-SNMMI-SPR Practice Parameter for the Use of Radiopharmaceuticals in Diagnostic Procedures. Available at <https://gravitas.acr.org/PPTS/GetDocumentView?docId=171+&releaseId=2>

**25.** United States Nuclear Regulatory Commission. 10 CFR 35.50 Training for radiation safety officer and associate radiation safety officer. Available at: <http://www.nrc.gov/reading-rm/doc-collections/cfr/part035/part035-0050.html>.

**26.** American College of Radiology. ACR-ASNR-SPR Practice Parameter for the Performance of Computed Tomography (CT) of the Extracranial Head and Neck. Available at: <https://gravitas.acr.org/PPTS/GetDocumentView?docId=169+&releaseId=2>

**27.** American College of Radiology. ACR-SABI-SPR-STR Practice Parameter for the Performance of Thoracic Computed Tomography (CT). Available at <https://gravitas.acr.org/PPTS/GetDocumentView?docId=13+&releaseId=2>

**28.** American College of Radiology. ACR-SABI-SAR-SPR PRACTICE PARAMETER FOR THE PERFORMANCE OF COMPUTED TOMOGRAPHY (CT) OF THE ABDOMEN AND COMPUTED TOMOGRAPHY (CT) OF THE PELVIS. Available at: <https://gravitas.acr.org/PPTS/GetDocumentView?docId=168+&releaseId=2>

**29.** Boellaard RR, Delgado-Bolton RR, Oyen WW, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328-54, .

**30.** Shankar LL, Hoffman JJ, Bacharach SS, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 47:1059-66, .

**31.** Surasi DD, Bhambhvani PP, Baldwin JJ, Almodovar SS, O'Malley JJ. <sup>18</sup>F-FDG PET and PET/CT patient preparation: a review of the literature. J Nucl Med Technol 42:5-13, .

**32.** Gelfand MM, O'hara SS, Curtwright LL, Maclean JJ. Pre-medication to block [(18)F]FDG uptake in the brown adipose tissue of pediatric and adolescent patients. Pediatr Radiol 35:984-90, .

**33.** Wong K, Brady S, Doubrovin M, et al. Propranolol decreases 18F-fluorodeoxyglucose uptake in brown adipose tissue on pediatric oncology PET/CT. J Nucl Med 2018;59:310.

**34.** American College of Radiology. ACR-SIR Practice Parameter For Minimal and/or Moderate Sedation/Analgesia. Available at <https://gravitas.acr.org/PPTS/GetDocumentView?docId=95+&releaseId=2>

**35.** Barrington SS, Maisey MM. Skeletal muscle uptake of fluorine-18-FDG: effect of oral diazepam. J Nucl Med 37:1127-9, .

**36.** United States Nuclear Regulatory Commission. ACMUI Activities: Overview. Available at: <https://www.nrc.gov/reading-rm/doc-collections/commission/slides/2019/20190404/acmui-20190404.pdf>.

**37.** American College of Radiology, Radiological Society of North America, American Society of Radiologic Technologists, American of Physicists in Medicine. Optimizing oncologic FDG-PET/CT scans to decrease radiation exposure. Available at: <https://www.imagewisely.org/Imaging-Modalities/Nuclear-Medicine/Optimizing->

## Oncologic-FDG-PETCT-Scans..

Revised 2021 (Resolution 20)

**38.** Pahey FH, Parisi MT. 2016 Update of the North American Consensus Guidelines for Pediatric Administered Radiopharmaceutical Activities. *J Nucl Med.* 2016 Dec;57(12):15N-18N.

**39.** Otero HH, Yap JJ, Patak MM, et al. Evaluation of low-density neutral oral contrast material in PET/CT for tumor imaging: results of a randomized clinical trial. *AJR Am J Roentgenol* 193:326-32, .

**40.** Antoch GG, Jentzen WW, Freudenberg LL, et al. Effect of oral contrast agents on computed tomography-based positron emission tomography attenuation correction in dual-modality positron emission tomography/computed tomography imaging. *Invest Radiol* 38:784-9, .

**41.** Cohade CC, Osman MM, Nakamoto YY, et al. Initial experience with oral contrast in PET/CT: phantom and clinical studies. *J Nucl Med* 44:412-6, .

**42.** Dizendorf EE, Hany TT, Buck AA, von Schulthess GG, Burger CC. Cause and magnitude of the error induced by oral CT contrast agent in CT-based attenuation correction of PET emission studies. *J Nucl Med* 44:732-8, .

**43.** Mawlawi OO, Erasmus JJ, Munden RR, et al. Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation. *AJR Am J Roentgenol* 186:308-19, .

**44.** Radiological Society of North America. FDG-PET/CT UPICT V1.0. Available at: [http://www.rsna.org/uploadedFiles/RSNA/Content/Science\\_and\\_Education/QIBA/UPICT\\_FDG-PET\\_Protocol\\_ver08July2014.pdf](http://www.rsna.org/uploadedFiles/RSNA/Content/Science_and_Education/QIBA/UPICT_FDG-PET_Protocol_ver08July2014.pdf).

**45.** Boellaard RR. Standards for PET image acquisition and quantitative data analysis. *J Nucl Med* 50 Suppl 1:11S-20S, .

**46.** American College of Radiology. ACR Practice Parameter for Communication of Diagnostic Imaging Findings. Available at <https://gravitas.acr.org/PPTS/GetDocumentView?docId=74+&releaseId=2>

**47.** Niederkohr RR, Greenspan BB, Prior JJ, et al. Reporting guidance for oncologic 18F-FDG PET/CT imaging. *J Nucl Med* 54:756-61, .

**48.** Perry K, Tann M, Miller M. Which reference tissue is best for semiquantitative determination of FDG activity? *Journal of nuclear medicine technology* 2008;Supplement 1: 425.

**49.** Agress HH, Wong TT, Shreve PP. Interpretation and reporting of positron emission tomography-computed tomographic scans. *Semin Ultrasound CT MR* 29:283-90, .

**50.** Kinahan PP, Fletcher JJ. Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. *Semin Ultrasound CT MR* 31:496-505, .

**51.** Rohren EE. Positron emission tomography-computed tomography reporting in radiation therapy planning and response assessment. *Semin Ultrasound CT MR* 31:516-29, .

**52.** Wahl RR, Jacene HH, Kasamon YY, Lodge MM. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. *J Nucl Med* 50 Suppl 1:122S-50S, .

**53.** Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F] fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. *Eur J Cancer* 1999;35:1773-82.

**54.** American College of Radiology. ACR-AAPM Technical Standard for Nuclear Medical Physics Performance Monitoring of Gamma Cameras. Available at <https://gravitas.acr.org/PPTS/GetDocumentView?docId=196+&releaseId=2>

**55.** American College of Radiology. ACR-AAPM Technical Standard for Diagnostic Medical Physics Performance Monitoring of Computed Tomography (CT) Equipment. Available at <https://gravitas.acr.org/PPTS/GetDocumentView?docId=131+&releaseId=2>

\*Practice parameters and technical standards are published annually with an effective date of October 1 in the year in which amended, revised or approved by the ACR Council. For practice parameters and technical standards published before 1999, the effective date was January 1 following the year in which the practice parameter or technical standard was amended, revised, or approved by the ACR Council.

## Development Chronology for This Practice Parameter

2007 (Resolution 19)

Amended 2009 (Resolution 11)

Revised 2012 (Resolution 24)

Amended 2014 (Resolution 39)

Revised 2016 (Resolution 25)

Revised 2021 (Resolution 20)

Amended 2023 (Resolution 2c, 2d)